Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Dare Bioscience, Inc. (NASDAQ:DARE) saw a large growth in short interest in April. As of April 30th, there was short interest totaling 358,082 shares, a growth of 110.4% from the April 15th total of 170,167 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average daily volume of 1,546,863 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Dare Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. LPL Financial LLC acquired a new stake in shares of Dare Bioscience during the 4th quarter worth about $28,000. Raymond James Financial Inc. increased its position in Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after buying an additional 13,650 shares during the period. Virtu Financial LLC acquired a new position in Dare Bioscience during the third quarter worth approximately $37,000. Finally, AMH Equity Ltd lifted its stake in Dare Bioscience by 20.0% in the third quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock valued at $488,000 after buying an additional 38,770 shares during the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.00.

Dare Bioscience Price Performance

Shares of NASDAQ DARE traded down $0.69 during midday trading on Friday, hitting $2.17. 1,217,264 shares of the company’s stock were exchanged, compared to its average volume of 1,377,150. Dare Bioscience has a twelve month low of $1.27 and a twelve month high of $9.19. The company has a market cap of $31.60 million, a PE ratio of -2.28 and a beta of 1.09. The firm’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $1.92.

Dare Bioscience (NASDAQ:DARE) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.13. The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.03 million. Equities analysts anticipate that Dare Bioscience will post -1.5 EPS for the current fiscal year.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.